ILKO was founded by pharmacist and honorary president Mustafa Öncel, who has worked in the pharmaceutical industry for almost 50 years. The company is a subsidiary of Selçuklu Holding, which has strong institutions across various economic sectors.
Genexine, Inc. specializes in developing and conducting research on therapeutic vaccines for intractable diseases and next-generation Fc fusion protein drugs. From its establishment, Genexine has grown extensively to achieve KRW 220 billion market capital and almost 98 employees working in the company. Genexine was founded by Professor Y.C. Sung in 1999, who is still currently active as a CEO as well as in the Life Sciences Department in Pohang University of Science and Technology's (POSTECH).